Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

NT‐proBNP qualifies as a surrogate for clinical endpoints in heart failure

(2021) Walter Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies

(2020) Michael Boettcher et al.   CLINICAL PHARMACOKINETICS

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

(2020) Paul W. Armstrong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction

(2019) Javed Butler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators

(2018) Peter Sandner   BIOLOGICAL CHEMISTRY

Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

(2018) Emelia J. Benjamin et al.   CIRCULATION

Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver

(2018) Deepak Kumar Bhatt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator

(2018) Paul W. Armstrong et al.   JACC-Heart Failure

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

(2017) Markus Follmann et al.   JOURNAL OF MEDICINAL CHEMISTRY

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer

(2016) Shuang Liang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

NT-proBNP

(2016) Paul M. McKie et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

(2015) Mihai Gheorghiade et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)

(2014) Burkert Pieske et al.   EUROPEAN JOURNAL OF HEART FAILURE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

The annual global economic burden of heart failure

(2013) Christopher Cook et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Soluble guanylate cyclase: a potential therapeutic target for heart failure

(2012) Mihai Gheorghiade et al.   HEART FAILURE REVIEWS

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure

(2009) Gerard C.M. Linssen et al.   CIRCULATION